HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BMS-906024

has antineoplastic activity; structure in first source

Also Known As:

BMS906024; N'-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)butanediamide

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        Benzodiazepinones
        BMS-906024: 5

Experts

1.	Pine, Sharon R: 2 articles (12/2018 - 12/2017)
2.	Barbeau, Lydie M O: 1 article (01/2018)
3.	Dubois, Ludwig: 1 article (01/2018)
4.	Groot, Arjan J: 1 article (01/2018)
5.	Houben, Ruud: 1 article (01/2018)
6.	Lemmens, Alyssa: 1 article (01/2018)
7.	Losen, Mario: 1 article (01/2018)
8.	Sosa Iglesias, Venus: 1 article (01/2018)
9.	Theys, Jan: 1 article (01/2018)
10.	Vooijs, Marc: 1 article (01/2018)

Related Diseases

1.	Adenocarcinoma of Lung 12/15/2018 - "We discuss our recently published preclinical study using the γ-secretase inhibitor AL101, formerly BMS906024, on cell lines and PDX models of NSCLC, primarily lung adenocarcinoma. " 12/01/2017 - "In vivo studies with cell line- and patient-derived lung adenocarcinoma xenografts confirmed enhanced antitumor activity for BMS-906024 plus paclitaxel versus either drug alone via decreased cell proliferation and increased apoptosis. " 12/01/2017 - "Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma."
2.	Adenocarcinoma 12/01/2017 - "On an extended panel of 31 NSCLC cell lines, 25 of which were adenocarcinoma, the synergy between BMS-906024 and paclitaxel was significantly greater in KRAS- and BRAF-wildtype than KRAS- or BRAF-mutant cells (mean CI, 0.43 vs. 0.90, respectively; P = 0.003). "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/01/2015 - "We describe the case of a patient with relapsed/refractory early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL) who achieved a complete hematologic response following treatment with the GSI BMS-906024. "
4.	Neoplasms (Cancer) 01/01/2018 - "In H1299 tumor spheroids, significant SSGD was obtained for cisplatin, etoposide, and crizotinib, which increased significantly after the addition of the NOTCH inhibitor BMS-906024 (but not for paclitaxel and pemetrexed), and especially in triple combination with radiation. "
5.	Hemolysis 09/01/2015 - "In this work, we evaluated the effect of different degrees of hemolysis on the internal standard peak area, accuracy, and precision of the analyses of BMS-906024 and its metabolite, BMS-911557, in human plasma by LC-MS/MS. In addition, we proposed the strategy of using the peak area of the stable isotope-labeled internal standard (SIL-IS) from the LC-MS/MS measurement as the surrogate marker for risk assessment. "

Related Drugs and Biologics

1.	Amyloid Precursor Protein Secretases (beta-Secretase)
2.	Paclitaxel (Taxol)
3.	Biomarkers (Surrogate Marker)
4.	Isotopes
5.	Etoposide (VP 16)
6.	Cisplatin (Platino)
7.	Crizotinib
8.	Pemetrexed (MTA)
9.	BMS-911557